{"id":583,"date":"2019-03-19T15:49:04","date_gmt":"2019-03-19T15:49:04","guid":{"rendered":"https:\/\/lumed.ca\/refonte\/?post_type=nouvelle&p=583"},"modified":"2024-02-03T04:19:19","modified_gmt":"2024-02-03T04:19:19","slug":"company-of-biomerieux","status":"publish","type":"nouvelle","link":"https:\/\/lumed.ca\/en\/nouvelles\/company-of-biomerieux\/","title":{"rendered":"Company of bioM\u00e9rieux"},"content":{"rendered":"\n

Sherbrooke (Qu\u00e9bec, Canada)\u2013 October 25th, 2017<\/strong> Lumed, a leading-edge software firm with a mission to optimize infectious diseases clinical practice, improve antimicrobial governance, and enhance the quality of patient care, was acquired by bioM\u00e9rieux, a world leader in the field of in vitro diagnostics. This acquisition marks a significant milestone, uniting both companies\u2019 efforts to sell and distribute the Lumed Antimicrobial Prescription Surveillance System (APSS) and DATA software in Europe, Canada, and the US.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The two\ncompanies forge even stronger bonds with Lumed welcoming strategic equity investments\nby bioM\u00e9rieux. This investment completes a funding round started earlier this\nyear with participating entities including, notably, ACET Capital, Bank of\nDevelopment of Canada for Quebec Regions, Desjardins, Economic Development\nCanada and Can-Export. Lumed is a business of the ACET accelerator that has\nseen direct benefits from the partnership between the University of Lyon and\nthe University of Sherbrooke, which has enabled it to strengthen its link with\nbioM\u00e9rieux more quickly. <\/p>\n\n\n\n

Appropriate antimicrobial governance is essential in order for hospitals to provide proper patient care, control pharmacy costs and reduce antimicrobial resistance. The APSS is a computerized clinical decision-support system designed to assist antimicrobial stewardship teams to monitor clinical information, as soon as information becomes available, and verify that the ongoing treatment remains appropriate according to contraindications related to inappropriate drug\u2013drug interactions, drug\u2013bug or drug\u2013laboratory mismatches, cheaper alternatives, maximum daily dose, maximum and minimum dose and frequency, maximum duration and route of administration while taking into account a number of critical patient-specific information. In a recently published study, the implementation of the software has demonstrated a sustained reduction of 20% of antimicrobial use over a 3 years period1<\/sup>. <\/p>\n\n\n\n

The\ndeployment of the APSS globally by bioM\u00e9rieux, in collaboration with Lumed,\nwill reinforce even further the company`s leadership position in the fight\nagainst antimicrobial resistance by working closely with the hospital systems. <\/p>\n\n\n\n

\u201cWe were\ndeeply impressed by this innovative solution brought by a team of the highest\nquality. We look forward to working with Lumed by providing the commercial\nscale that allows to serve patients around the world,\u201d said Alain Pluquet,\nbioM\u00e9rieux\u2019s Corporate Vice President, Chief Data Officer. \u201cbioMerieux is\ncommitted to the fight against antimicrobial resistance, and this above and\nbeyond the laboratory. <\/p>\n\n\n\n

Our\npartnership with Lumed illustrates our approach of selective partnering to grow\nour Data Analytics business, with a continued focus and commitment on patient\ncare.\u201d \u201cBioM\u00e9rieux\u2019s history and track record as leaders in microbiology are\nimpressive. As they\u2019ve successfully expanded their global footprint, they still\nmaintain an intimate and respectful relationship with smaller, innovative\ncompanies like ours. I am convinced the synergies between our products and\nexpertise will significantly improve patient care around the world\u201d stated\nVincent Nault, Co-Founder and CEO of Lumed.<\/p>\n\n\n\n

\u00ab Nous avons \u00e9t\u00e9 impressionn\u00e9s par le caract\u00e8re innovant de cette solution d\u00e9velopp\u00e9e par une \u00e9quipe d\u2019une qualit\u00e9 exceptionnelle et nous avons h\u00e2te de travailler avec Lumed en fournissant une organisation commerciale permettant de servir les patients du monde entier <\/em>\u00bb, a d\u00e9clar\u00e9 Alain Pluquet, Directeur de l\u2019unit\u00e9 Data Analytics<\/em> de bioM\u00e9rieux. \u00ab bioM\u00e9rieux est engag\u00e9 dans la lutte contre la r\u00e9sistance aux antibiotiques, et ceci au-del\u00e0 du laboratoire. Notre collaboration avec Lumed illustre notre approche s\u00e9lective de partenariat pour d\u00e9velopper notre activit\u00e9 Data Analytics, dans un engagement continu au service de l\u2019am\u00e9lioration de la prise en charge des patients.<\/em> \u00bb
<\/p>\n\n\n\n

\u00ab L\u2019histoire\net l\u2019exp\u00e9rience de bioM\u00e9rieux, en tant que leader en microbiologie sont impressionnantes.\nbioM\u00e9rieux a depuis longtemps r\u00e9ussi \u00e0 \u00e9tendre sa pr\u00e9sence \u00e0 l\u2019\u00e9chelle mondiale\ntout en maintenant des relations \u00e9troites et respectueuses avec des entreprises\nplus petites et innovantes comme la n\u00f4tre. Je suis convaincu que les synergies\nentre nos produits et nos expertises am\u00e9lioreront consid\u00e9rablement la qualit\u00e9\ndes soins apport\u00e9s aux patients <\/em>\u00bb a d\u00e9clar\u00e9 Vincent Nault, cofondateur et Pr\u00e9sident\ndirecteur g\u00e9n\u00e9ral de Lumed.
<\/p>\n\n\n\n

\n\n\n\n

[1]<\/a> Nault V et al, J Antimicrob Chemother. 2017               <\/p>\n","protected":false},"excerpt":{"rendered":"

Sherbrooke (Qu\u00e9bec, Canada)\u2013 October 25th, 2017 Lumed, a leading-edge software firm with a mission to optimize infectious diseases clinical practice, improve antimicrobial governance, and enhance the quality of patient care, was acquired by bioM\u00e9rieux, a […]<\/p>\n","protected":false},"author":3,"template":"","restrain":[],"placement":[6,7],"news_cat":[],"class_list":["post-583","nouvelle","type-nouvelle","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/nouvelle\/583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/nouvelle"}],"about":[{"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/types\/nouvelle"}],"author":[{"embeddable":true,"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/users\/3"}],"version-history":[{"count":8,"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/nouvelle\/583\/revisions"}],"predecessor-version":[{"id":3358,"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/nouvelle\/583\/revisions\/3358"}],"wp:attachment":[{"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/media?parent=583"}],"wp:term":[{"taxonomy":"restrain","embeddable":true,"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/restrain?post=583"},{"taxonomy":"placement","embeddable":true,"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/placement?post=583"},{"taxonomy":"news_cat","embeddable":true,"href":"https:\/\/lumed.ca\/en\/wp-json\/wp\/v2\/news_cat?post=583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}